Inactivated SARS-Cov-2 Vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Inactivated SARS-Cov-2 Vaccine
Accession Number
DB15862
Description

Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2. This strain was isolated from a patient in Wuhan, cultivated in a Vero cell line, and then subsequently inactivated using B-propiolactone1. Double-blind, randomized, placebo-controlled phase 1 (96 participants) and phase 2 (224 participants) were carried out in healthy adults between 18-59 years[A2201585]. Results from these trials showed low rates of adverse reactions and demonstrated immunogenicity1. Currently, the vaccine is being tested in Phase 3 clinical trial in Abu Dhabi (ChiCTR2000034780)2.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
Not Available
External IDs
  • Inactivated SARS-Cov-2 Vaccine

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X: Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020 Aug 13. pii: 2769612. doi: 10.1001/jama.2020.15543. [PubMed:32789505]
  2. Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, Mamani JB, Gamarra LF: Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. Vaccines (Basel). 2020 Aug 25;8(3). pii: vaccines8030474. doi: 10.3390/vaccines8030474. [PubMed:32854391]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / Flu caused by Influenza1
3Active Not RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / COVID-19 Virus Infection1
3Active Not RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / SARS-CoV2 Infection1
3Enrolling by InvitationPreventionCoronavirus Disease 2019 (COVID‑19)1
3RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)2
2Active Not RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
1Active Not RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
1, 2Active Not RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)2
1, 2Enrolling by InvitationPreventionCoronavirus Disease 2019 (COVID‑19)1
1, 2RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 18, 2020 21:05 / Updated on September 20, 2020 02:19